|
|
|
| Expression of DNMT1 and HMGA2 in the bladder urothelial carcinoma tissues and their clinical significance |
| WEI Fukui WANG Yaofeng |
| Department of Urology Surgery, Baoji Affiliated Hospital of Xi'an Medical University, Shaanxi Province, Baoji 721006, China |
|
|
|
|
Abstract Objective To detect the protein expressions of the DNA methyltransferase 1 (DNMT1) and high mobility group protein A2 (HMGA2) in the bladder urothelial carcinoma (BUC) tissues and to investigate their clinical significance. Methods From January 2010 to June 2012, 89 cases of BUC cancer tissues and 45 cases of normal bladder tissues were collected from Department of Urology Surgery of Baoji Affiliated Hospital of Xi'an Medical University. The immunohistochemical SP method was used to detect the protein expression of DNMT1 and HMGA2 in each tissue. In addition, the relationship between the protein expression of DNMT1/HMGA2 and the clinical pathologic characteristics and prognosis was analyzed. Results The positive expression rate of DNMT1 in BUC cancer tissues and normal bladder tissues was 70.79% (63/89) and 6.67% (3/45), respectively (P ＜ 0.05). The positive expression rate of HMGA2 in BUC cancer tissues and the normal bladder tissues was 65.17% (58/89) and 2.22% (1/45), respectively (P ＜ 0.05). In BUC cancer tissues, the DNMT1 protein expression was correlated with the tumor diameter, lymph node metastasis status and the clinical stages (P ＜ 0.05), while the HMGA2 protein expression was correlated with the tumor diameter, differentiation grades and the clinical stages (P ＜ 0.05). The DNMT1-positive patients' survival time was much shorter than the DNMT1-negative patients (P ＜ 0.05), while the HMGA2-positive patients' survival time was much shorter than the HMGA2-negative patients (P ＜ 0.05). Conclusion In BUC cancer tissues, the DNMT1 and HMGA2 are both highly expressed, which may play critical roles in the tumor genesis and the development of BUC. DNMT1 and HMGA2 may serve as biomarkers for the prognosis and the therapy of BUC.
|
|
|
|
|
|
[1] Chakravarthi BV，Nepal S，Varambally S. Genomic and Epigenomic Alterations in Cancer [J]. Am J Pathol，2016， 186（7）：1724-1735.
[2] Friedman N，Rando OJ. Epigenomics and the structure of the living genome [J]. Genome Res，2015，25（10）：1482-1490.
[3] van der Wijst MG，Venkiteswaran M，Chen H，et al. Local chromatin microenvironment determines DNMT activity：from DNA methyltransferase to DNA demethylase or DNA dehydroxymethylase [J]. Epigenetics，2015，10（8）：671-676.
[4] Yang J，Platt LT，Maity B，et al. RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation [J]. Oncotarget，2016，7（43）：69159-69172.
[5] Cattaruzzi G，Altamura S，Tessari MA，et al. The second AT-hook of the architectural transcription factor HMGA2 is determinant for nuclear localization and function [J]. Nucleic Acids Res，2007，35（6）：1751-1760.
[6] Fedele M，Palmieri D，Fusco A. HMGA2：A pituitary tumour subtype-specific oncogene? [J]. Mol Cell Endocrinol，2010， 326（1/2）：19-24.
[7] Xu L，Liao WL，Lu QJ，et al. ANG Promotes Proliferation and Invasion of the Cell of Lung Squamous Carcinoma by Directly Up-Regulating HMGA2 [J]. J Cancer，2016，7（7）：862-871.
[8] Sun M，Gomes S，Chen P，et al. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2 [J]. Oncogene，2014，33（27）：3528-3537.
[9] Piscuoglio S，Zlobec I，Pallante P，et al. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma [J]. Histopathology，2012，60（3）：397-404.
[10] Yang GL，Zhang LH，Bo JJ，et al. Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis HMGA2 as a prognostic marker of bladder cancer [J]. Eur J Surg Oncol，2011，37（3）：265-271.
[11] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[12] Mathieu R，Lucca I，Rouprêt M，et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder [J]. Nat Rev Urol，2016，13（8）：471-479.
[13] Amodio N，D'Aquila P，Passarino G，et al. Epigenetic modifications in multiple myeloma：recent advances on the role of DNA and histone methylation [J]. Expert Opin Ther Targets，2017，21（1）：91-101.
[14] Wang S，Wu W，Claret FX. Mutual regulation of microRNAs and DNA methylation in human cancers [J]. Epigenetics，2017，12（3）：187-197.
[15] Li H，Li W，Liu S，et al. DNMT1，DNMT3A and DNMT3B Polymorphisms Associated With Gastric Cancer Risk：A Systematic Review and Meta-analysis [J]. EBioMedicine，2016，13：125-131.
[16] Lee E，Wang J，Yumoto K，et al. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells，Which Promotes Prostate Cancer Metastasis [J]. Neoplasia，2016，18（9）：553-566.
[17] Plummer R，Vidal L，Griffin M，et al. Phase Ⅰ study of MG98，an oligonucleotide antisense inhibitor of human DNA methyltransferase 1，given as a 7-day infusion in patients with advanced solid tumors [J]. Clin Cancer Res，2009，15（9）：3177-3183.
[18] Wu CT，Wu CF，Lu CH，et al. Expression and function role of DNA methyltransferase 1 in human bladder cancer [J]. Cancer，2011，117（22）：5221-5233.
[19] Dhawan D，Ramos-Vara JA，Hahn NM，et al. DNMT1：an emerging target in the treatment of invasive urinary bladder cancer [J]. Urol Oncol，2013，31（8）：1761-1769.
[20] Shi Z，Li X，Wu D，et al. Silencing of HMGA2 suppresses cellular proliferation，migration，invasion，and epithelial-mesenchymal transition in bladder cancer [J]. Tumour Biol，2016，37（6）：7515-7523.
[21] Ding X，Wang Y，Ma X，et al. Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition [J]. Cell Prolif，2014，47（2）：146-151. |
|
|
|
